Published in Nouv Rev Fr Hematol on January 01, 1994
Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol (2015) 0.87
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice. Eur Respir J (2010) 1.51
Systemic administration of endotoxin induces bronchopulmonary hyperreactivity dissociated from TNF-alpha formation and neutrophil sequestration into the murine lungs. J Immunol (1998) 1.33
Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol (1986) 1.17
Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol (1997) 1.17
Inhibition by sulfhydryl agents of arachidonic acid-induced platelet aggregation and release of potential inflammatory substances. Prostaglandins (1974) 1.16
Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol (1981) 1.15
Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J (1988) 1.14
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Effect of cyclo-oxygenase inhibitors and modulators of cyclic AMP formation on lipopolysaccharide-induced neutrophil infiltration in mouse lung. Br J Pharmacol (1996) 1.10
Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci U S A (1986) 1.05
Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur J Pharmacol (1976) 1.03
Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether). Eur J Pharmacol (1982) 1.02
Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. Thromb Res (1982) 1.02
Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J Clin Invest (1999) 0.99
Rickettsia felis, from culture to genome sequencing. Ann N Y Acad Sci (2005) 0.99
[Intracardiac thrombosis in Behçet disease: clinical presentation and outcome of three cases]. J Mal Vasc (2011) 0.96
Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. Eur J Pharmacol (1982) 0.95
Lack of IL-10 synthesis by murine alveolar macrophages upon lipopolysaccharide exposure. Comparison with peritoneal macrophages. J Leukoc Biol (2000) 0.95
Activation of human platelets by C5a-stimulated neutrophils: a role for cathepsin G. Am J Physiol (1990) 0.93
Serological microarray for a paradoxical diagnostic of Whipple's disease. Eur J Clin Microbiol Infect Dis (2008) 0.93
[Trichotemnomania associated to trichotillomania: a case report with emphasis on the diagnostic value of dermoscopy]. Ann Dermatol Venereol (2010) 0.92
Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. Agents Actions (1982) 0.90
Blockade by metal complexing agents and by catalase of the effects of arachidonic acid on platelets: relevance to the study of anti-inflammatory mechanisms. Eur J Pharmacol (1975) 0.89
Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. Eur J Pharmacol (1980) 0.88
Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol (1998) 0.88
Innate immunity and inflammation--two facets of the same anti-infectious reaction. Clin Exp Immunol (2009) 0.88
Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood (1993) 0.88
Tumor necrosis factor-alpha enhances platelet activation via cathepsin G released from neutrophils. J Immunol (1991) 0.88
[Platelet aggregation and platelet activating factor (author's transl)]. J Pharmacol (1981) 0.87
Role of the metabolites of arachidonate in platelet-dependent and independent experimental bronchoconstriction. Bull Eur Physiopathol Respir (1981) 0.86
Proteinase 3. A neutrophil proteinase with activity on platelets. J Immunol (1994) 0.85
Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs. Eur J Pharmacol (1986) 0.85
Dissociation of platelet activation from transmethylation of their membrane phospholipids. Nature (1981) 0.85
Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. Eur J Pharmacol (1983) 0.85
Heparin inhibits neutrophil-induced platelet activation via cathepsin G. J Lab Clin Med (1992) 0.85
Human neutrophil cathepsin G down-regulates LPS-mediated monocyte activation through CD14 proteolysis. J Leukoc Biol (2000) 0.84
Platelet-lung in vivo interactions: an artifact of a multi-purpose model? Haemostasis (1979) 0.84
Cooperation between platelets and neutrophils for paf-acether (platelet-activating factor) formation. J Leukoc Biol (1990) 0.84
Combined activation of platelets by cathepsin G and platelet activating factor, two neutrophil-derived agonists. Br J Haematol (1992) 0.84
Interference of recombinant eglin C, a proteinase inhibitor extracted from leeches, with neutrophil-mediated platelet activation. Lab Invest (1990) 0.84
Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation. Br J Pharmacol (1993) 0.83
One, two, three or more pathways for platelet aggregation. Acta Med Scand Suppl (1980) 0.83
Inhibition of neutrophil serine proteinases by suramin. J Biol Chem (1997) 0.83
Preliminary transcriptional analysis of spoT gene family and of membrane proteins in Rickettsia conorii and Rickettsia felis. Ann N Y Acad Sci (2005) 0.83
Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). Agents Actions (1980) 0.82
Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment. FEBS Lett (1996) 0.82
Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol (2014) 0.82
Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Haematol (1981) 0.81
Substances that increase the cyclic AMP content prevent platelet aggregation and the concurrent release of pharmacologically active substances evoked by arachidonic acid. Agents Actions (1975) 0.81
Surfactant protein A suppresses lipopolysaccharide-induced IL-10 production by murine macrophages. J Immunol (2001) 0.81
Activation and damage of cultured airway epithelial cells by human elastase and cathepsin G. Eur J Pharmacol (1992) 0.80
L8027 and 1-nonyl-imidazole as non-selective inhibitors of thromboxane synthesis. Eur J Pharmacol (1979) 0.80
Paf-acether formation and arachidonic acid freeing from platelet ether-linked glyceryl-phosphorylcholine. Biochem Biophys Res Commun (1984) 0.80
Comparison of Rickettsia conorii growth within different cell lines by real-time quantitative PCR. Clin Microbiol Infect (2009) 0.80
Leucocyte elastase-mediated release of von Willebrand factor from cultured endothelial cells. Eur Respir J (1993) 0.79
All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia (1996) 0.79
[Thrombosis of the inferior vena cava revealing primary antiphospholipid syndrome: a case report]. J Mal Vasc (2009) 0.79
Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib-IX receptor: characterization of the cleavage sites within the glycoprotein Ib alpha subunit. Biochem J (1994) 0.79
A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases? Circulation (1985) 0.79
Secretome of human bronchial epithelial cells in response to the fungal pathogen Aspergillus fumigatus analyzed by differential in-gel electrophoresis. J Infect Dis (2012) 0.79
Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. Thromb Res (1984) 0.78
Plasma antiproteinase screen and neutrophil-mediated platelet activation. A major role played by alpha 1 antitrypsin. Biochim Biophys Acta (1994) 0.78
Leukocytic functions in burn-injured patients. Prostaglandins (1985) 0.78
The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation: comparison with thrombin. Biochem J (1996) 0.78
Interference of bromophenacyl bromide with platelet phospholipase A2 activity induced by thrombin and by the ionophore A23187. Thromb Res (1980) 0.78
Improvement of RNA purification from infected tissues to explore the in vivo host-pathogen interactions with microarrays. Clin Microbiol Infect (2009) 0.77
Role of paf-acether and related ether-lipid metabolism in platelets. Adv Exp Med Biol (1985) 0.77
3 Deazaadenosine and L-homocysteine inhibit platelet aggregation induced by collagen and convulxin through a phospholipase A2 independent mechanism. Thromb Res (1982) 0.76
Transient activation of the acetyltransferase necessary for paf-acether biosynthesis in thrombin-activated platelets. Br J Haematol (1986) 0.76
Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine. Br J Pharmacol (1991) 0.76
Synthesis of thromboxane A2 by non-aggregating dog platelets challenged with arachidonic acid or with prostaglandin H2. Prostaglandins (1977) 0.76
Use of steroidal antiinflammatory drug provides further evidence for a potential role of PAF-acether in bronchial anaphylaxis. Int Arch Allergy Appl Immunol (1986) 0.76
Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets. Biochem Biophys Res Commun (1982) 0.76
Neutrophil serine proteases are most probably involved in the release of CD43 (leukosialin, sialophorin) from the neutrophil membrane during cell activation. Blood (1996) 0.76
Protective effect of platelet activating factor antagonists on cultured endothelial cell lysis induced by elastase or activated neutrophils. Br J Pharmacol (1996) 0.75
New vistas on the role of platelets in bronchoconstrictions. Agents Actions Suppl (1979) 0.75
Synergism between interleukin-8 and tumor necrosis factor-alpha for neutrophil-mediated platelet activation. Eur Cytokine Netw (1995) 0.75
Familial and constitutional bleeding disorder due to platelet cyclo-oxygenase deficiency. Am J Hematol (1983) 0.75
Methylation inhibitors impair collagen-induced activation of human platelets. Thromb Haemost (1983) 0.75
[Posterior reversible encephalopathy syndrome in a patient with lupus: differential diagnosis to discuss]. Rev Neurol (Paris) (2011) 0.75
Valproate-induced systemic lupus erythematous: A case report. Rev Neurol (Paris) (2013) 0.75
Proteinases and cytokines in neutrophil and platelet interactions in vitro. Possible relevance to the adult respiratory distress syndrome. Ann N Y Acad Sci (1994) 0.75
Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets: evidence for the requirement of a methyl transfer reaction in platelet activation. Adv Prostaglandin Thromboxane Leukot Res (1983) 0.75
Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. Agents Actions (1982) 0.75
Carrageenan-induced activation of human platelets is independent of phospholipase A2 and of formation of thromboxanes. J Pharm Pharmacol (1980) 0.75